Shares of AbbVie and Johnson & Johnson took a hit Friday after FDA briefing documents hinted a cheaper competitor for the drug companies’ blockbuster anti-inflammatory treatments could be headed to market soon.
Similar Stories to J&j, Abbvie Shares Drop On Potential Drug Competition on Bing News
WSJ.com: Health, Wall Street Journal: Business: Health
Fri, 02/05/2016 - 5:54pm
RELATED ARTICLES
- no title provided in feed
The global fertility rate has fallen from 5 births per woman in 1950 to 2.3 in 2021 - and even lower in the U.S., partly due to the cost of child-rearing and shifts in priorities. But "falling population and an elderly or aging population puts a lot of fiscal and economic pressures on society," says Economics Professor Melissa Kearney. More - no title provided in feed
Independent presidential candidate Robert F. Kennedy Jr. told The New York Times he experienced a series of health issues in recent years, including an abnormality that he said was caused by a worm that entered his brain and then died. More - no title provided in feed
Americans' mental health issues are not identified and treated as readily as physical symptoms, especially among children - in part due to a shortage of clinicians. "We're looking for ways to integrate mental health into settings where children and families are every day," says Dr. More - no title provided in feed
Mayor Donna Deegan speaks with CNN's Jake Tapper More - no title provided in feed
Rep. Brad Wenstrup speaks with CNN's Jake Tapper More - no title provided in feed
For some who see a therapist, just talking things through isn't enough. Drama therapy allows the patient to relive a moment or play out their biggest fears. More
BING NEWS:
- AbbVie joins in latest gastrointestinal drug chase
Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.
06/14/2024 - 9:22 am | View Link - AbbVie-FutureGen, Takeda, Kyowa Kirin—Fierce Pharma Asia
Through a licensing deal with a Chinese biotech, AbbVie is the latest Big Pharma to bet on TL1A in immunology. | Through a deal with a Chinese biotech, AbbVie is the latest Big Pharma to bet on TL1A ...
06/13/2024 - 9:59 pm | View Link - AbbVie inks deal potentially worth $1.7 billion for new IBD drug
The terms of the deal call for North Chicago-based AbbVie to pay FutureGen $150 million upfront, with additional payments totaling $1.56 billion based on clinical development, regulatory and ...
06/13/2024 - 4:33 am | View Link - AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
AbbVie Inc’s (NYSE:ABBV) top-selling arthritis drug, Humira, has managed to retain over 80% of ... The biosimilar industry advocates for regulatory changes, claiming that $6 billion in potential ...
06/7/2024 - 3:39 am | View Link - Is AbbVie Inc. (NYSE:ABBV) the Most Undervalued Dividend Aristocrat Stock According to Analysts?
We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since AbbVie Inc. (NYSE:ABBV) is part of our list, we have analyzed the stock in detail. The age-old debate ...
06/6/2024 - 7:44 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more